AIDS and InfectionsBETNCT05299645
The BeT Study Intervention to Reduce Disparities in HIV Prevention and Care
A study testing Interview in people with AIDS and Infections and HIV Prevention, run by Evandro Chagas National Institute of Infectious Disease at 1 site in Brazil.
Trial summary
Stigma prevents young transgender women from having access to HIV prevention and care services, despite the fact that these services are freely accessible to all Brazilians in the Unified Health System (ie, SUS). Levels of HIV testing and access to care for young people are uneven. Read more about this study
- Who is it for?
- Ages 18 to 24 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- AIDS and Infections, HIV Prevention, Stigma, Social
- What is being tested?
- Interview
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Feb 2019to 30 Jan 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 24 years
- Men only
- Healthy volunteers accepted
- Adult
Intervention study:
- Provision of signed and dated informed consent form
- Declaration of willingness to comply with all study procedures and availability during the study
- Age between 18 and 24 years
- Male sex designated at birth and self-reported gender identity as a transvestite, transsexual woman or other than the designated sex
- Desire to join the BeT intervention
- Access to a cell phone compatible with social networks (smartphone) to participate in a technology-based intervention
- Living in Rio de Janeiro or metropolitan area
Potential participants living with HIV must meet the following criteria:
- Documented diagnosis of HIV infection
- No current use of HAART OR detectable CV result OR not being followed up at a health service OR having missed at least one appointment in the last six months.
Potential HIV-negative participants must meet the following criteria:
- No current use of PrEP
- With indication of PrEP
- No contraindication to PrEP
Intervention (pilot + expansion): 1) impossibility of consenting or not consenting to the research, 2) female sex assigned at birth, 3) self-identification other than transvestite, transgender woman or gender identity different from the male received at birth, 4) age under 18 or over 24 years old, 5) speak only a language other than Portuguese, 6) live outside the metropolitan region of Rio de Janeiro, 7) not have a cell phone, 8) not be sexually active.
For HIV-negative volunteers, additional criteria are:
- being on PrEP. For HIV-positive volunteers, 1) having been diagnosed with HIV for more than one year, 2) being on regular antiretroviral therapy OR having an undetectable viral load (self-report), 3) being linked to a health service OR having attended to all consultations in the last six months.
Additionally, for the expansion phase, the following will also be considered: participation in another intervention study to promote HIV prevention or care in the last year or concomitant participation in another study that prevents concomitant inclusion (co-enrollment), refusal to perform testing for HIV, and any health condition that, in the opinion of the investigator, precludes participation in the study or harms a potential participant.
Trial locations and contacts
1 site in 1 country.
Brazil1 site, 1 recruiting
- Recruiting
Instituto Nacional de Infectologia Evandro Chagas (Fiocruz)
Rio de Janeiro, Rio de Janeiro, 21040-360
Beatriz G Grinsztejn, MD, PhD, +552122707064, gbeatriz@ini.fiocruz.br
Sandra W Cardoso, +552122707064, sandra.wagner@ini.fiocruz.br
About this study
Official title: A intervenção BeT Para Reduzir as Disparidades de prevenção e assistência ao HIV em Travestis e Mulheres Transexuais Jovens no Rio de Janeiro, Brasil
Stigma prevents young transgender women from having access to HIV prevention and care services, despite the fact that these services are freely accessible to all Brazilians in the Unified Health System (ie, SUS). Levels of HIV testing and access to care for young people are uneven. The purpose of this proposal is to generate data to address stigma in the public health system and intervene to overcome the challenges of youth with the navigation of health systems. The Brilhar e Transcender (BeT) study will include young trans women, aged 18 to 24, in Rio de Janeiro, Brazil. The BeT intervention has been found to be preliminarily efficacious in a pilot study. This proposal is for a study to test the effectiveness of an intervention to improve HIV prevention and care engagement among young trans women (N=150) at risk of HIV in Brazil.
Read the detailed description
Transvestites and young transsexual women in Brazil are exposed to a high risk of exposure to HIV and poor treatment of HIV infection. Brazil remains classified as a middle-income country in 2017 [1], despite the difficult political and economic climate. In 2016, there were 830,000 adults and children living with the HIV virus [2], with a 2% increase in new infections [2]. The first population-based study to assess HIV prevalence and knowledge of pre-exposure prophylaxis (PrEP) with young trans womenin Rio de Janeiro, Brazil (Transcender Study) found that 31.2% of them were infected with HIV. In this study, among young women aged 18 to 24 years, 24.2% of them were infected with HIV, a higher rate than any other study in young trans womenin the world [3, 4], and young women had three times as many unrecognized infections as adults [5]. These findings are worse than previous research suggests, that one in five transvestites or young transsexual women under the age of 25 was infected with the HIV virus [6, 7]. Even more worrisome, the young trans women in our study had had almost twice as much unprotected anal. Adverse events assessment and reporting sex in the past three months, while their perception of HIV risk was less than half. The data reflect that there is no decline in incident infections among young women and point to a need for early intervention to reduce the risk among transvestites and young transsexual women. This is a study in collaboration with the San Francisco Department of Public Health (SFDPH). All stages will be carried out in Brazil, at the National Institute of Infectious Diseases Evandro Chagas (INI)-FIOCRUZ. People (health professionals and trans people) will be referred from four services in Rio de Janeiro, Brazil, namely: INI-FIOCRUZ, Zilda Arns Family Clinic, Luiz Capriglione Diabetes and Endocrinology Institute (IEDE) and Heitor Municipal Health Center Beltron.
The study includes the collection of formative data, the evaluation of an anti-stigma campaign and an intervention study (pilot + scale-up) of HIV prevention and treatment. The expansion provides for a Type 1 hybrid design to assess the results of the exploratory implementation and examine the results of the single-arm intervention including 150 young transvestites and trans women. We will use a pre-post design to assess intervention outcomes and include an external comparison group using data extracted from the Ministry of Health to determine the effect of our intervention on engagement and adherence to PrEP and attachment to HIV care. Implementation results will also be explored with stakeholders at partner clinics, participants and key staff. In summary, formative data will be collected with 10 young young trans women to adapt a digital systems navigation and HIV prevention and care intervention to the cultural context and HIV prevention and care needs of this population group in Brazil. A highly visible and community-informed social marketing campaign will be developed and implemented to reduce anti-trans stigma at four SUS clinics in Rio de Janeiro. To measure success, pre- and post-campaign implementation interviews will be conducted with healthcare providers at the four clinics. Additionally, a pilot, phase I study will be conducted with 20 young participants to determine the preliminary effectiveness of the antistigma campaign and navigation systems intervention and demonstrate our ability to recruit young people in this population. Exit interviews will be conducted with all pilot participants (N = 20) to collect data to refine the intervention. Finally, an expansion of the pilot intervention study will be carried out, with the inclusion of another 150 participants. At this stage, all participants will receive the BeT intervention for a period of three months, in addition to standard care for HIV prevention and care. The study includes a Type 1 hybrid design study will be conducted to assess the results of the exploratory implementation and examine the results of the single-arm intervention including 150 transvestites and young trans women. We will use a pre-post design to assess intervention outcomes and include an external comparison group using data extracted from the Ministry of Health to determine the effect of our intervention on engagement and adherence to PrEP and attachment to HIV care. n total, the participants submitted to the intervention will stay in the project for one year. The initial visit will take approximately 2 hours to develop a case management plan with a team member (ARTAS plan). As part of the intervention, volunteers will be asked to participate in a baseline behavioral survey, followed by four others over one year (ie at 3, 6, 9, and 12 months). These surveys will last approximately 1 hour. During the intervention period, the volunteers will have contact with the digital browsers at least five times via WhatsApp or other social media to check the progress of the ARTAS plan and possibly more times depending on the participant's needs.
Each interaction should not last longer than an hour. In total, participants must spend 17 hours participating in the intervention, with no maximum time to adapt to the participant's needs. Recruitment for the study will feature the FIOCRUZ team of educators, composed of three members of the trans community, in addition to the possibility of peer recruitment. Both the confirmation of eligibility and the randomization process will be carried out with double verification. The inclusion visit will be carried out in person. After the consent and eligibility verification process, participants will be included in the study and will answer questionnaires administered by trained interviewers. The Shine and Transcender (BeT) intervention was based on ARTAS, an evidencebased, individual-level, multiple-session, time-limited intervention for system navigation and linkage for HIV treatment [29]. It lasts for 3 months and is composed of BeT sessions, digital interactions, asynchronous and automatic messages. Interim analysis of primary outcomes will be performed as described in Section 9.4.6, Planned Interim Analyzes. Analyzes considering HIV serological status (HIV-positive or -negative) will be performed in accordance with Section 9.4.7, Subgroup Analysis. With this study, it is expected to evaluate the modification associated with the BeT intervention in prevention (engagement and adherence to PrEP) and in HIV treatment (attachment to care). Clinical trials are a powerful tool for the evaluation of health interventions, whether drug or not. Through this study, it will be possible to assess the effectiveness of a digital intervention based on peer browsing in HIV prevention and care. As this is a study with only one arm, this can interfere with obtaining measurements or verifying outcomes. To minimize the possibility of bias, the assessment of outcomes will be performed by people other than those administering the intervention. In addition, we will benchmark against an outside group, with information from the Ministry of Health's national registry systems, to determine the effect of our intervention on engagement and adherence to PrEP and linkage to HIV care.
- Conditions
- AIDS and Infections, HIV Prevention, Stigma, Social, Hiv
- Being tested
- Interview
- Keywords
- Transvestites, Transsexual women, Assistance, Prevention
- Medical subject headings
- Acquired Immunodeficiency Syndrome, Infections, Social Stigma, Helping Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewBehavioural
Also called Queries
Pilot study with digital browsers
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 - Transvestites and young transsexual women | Experimental | Qualitative interviews Receives: Behavioral: Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Engagment on HIV prevention or care (for trans women)
Data from these surveys will be used to verify the primary outcomes of HIV testing, PrEP adoption, and attachment to HIV care. The results of this proposal could determine the preliminary effectiveness of the intervention in ensuring that trans youth undergo frequent HIV testing, engage in PrEP use and in HIV care.
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2022
- Study start1 Feb 2019
- Primary completion28 Feb 2021
- Study completion30 Jan 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AIDS and InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- With this study, it is expected to evaluate the modification associated with the BeT intervention in prevention (engagement and adherence to PrEP) and in HIV treatment (attachment to care). Clinical trials are a powerful tool for the evaluation of health interventions, whether drug or not. Through this study, it will be possible to assess the effectiveness of a digital intervention based on peer browsing in HIV prevention and care. As this is a study with only one arm, this can interfere with obtaining measurements or verifying outcomes. To minimize the possibility of bias, the assessment of outcomes will be performed by people other than those administering the intervention. In addition, we will benchmark against an outside group, with information from the Ministry of Health's national registry systems, to determine the effect of our intervention on engagement and adherence to PrEP and linkage to HIV care.
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Evandro Chagas National Institute of Infectious Disease
- Sponsor type
- University, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Responsible party
- Principal investigator, Raquel Malaguthi de Souza, Evandro Chagas National Institute of Infectious Disease
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05299645
- Sponsor's protocol ID
- 05018818000005262
- Other IDs
- 5UG3HD096914
- Acronym
- BET
- Status last verified
- Mar 2022
- First submitted
- 18 Mar 2021
- Last updated
- 29 Mar 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Jalil EM, Wilson E, Monteiro L, Varggas T, Moura I, Torres TS, Hoagland B, Cardoso SW, Ismerio Moreira R, Goncalves Veloso Dos Santos V, Grinsztejn B; BeT Team. A Peer-Led Digital Intervention to Reduce HIV Prevention and Care Disparities Among Young Brazilian Transgender Women (The BeT Study): Protocol for an Intervention Study. JMIR Res Protoc. 2023 Feb 3;12:e44157. doi: 10.2196/44157.
PubMed 36735296
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A intervenção BeT Para Reduzir as Disparidades de prevenção e assistência ao HIV em Travestis e Mulheres Transexuais Jovens no Rio de Janeiro, Brasil
- ClinicalTrials.gov ID
- NCT05299645
- Acronym / sponsor ID
- BET / 05018818000005262
- Conditions
- AIDS and Infections, HIV Prevention, Stigma, Social, Hiv
- Keywords
- Transvestites, Transsexual women, Assistance, Prevention
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Evandro Chagas National Institute of Infectious DiseaseUniversity, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Study start
- 1 Feb 2019 (actual)
- Primary completion
- 28 Feb 2021 (actual)
- Study completion
- 30 Jan 2023 (estimated)
- First posted
- 29 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stigma prevents young transgender women from having access to HIV prevention and care services, despite the fact that these services are freely accessible to all Brazilians in the Unified Health System (ie, SUS). Levels of HIV testing and access to care for young people are uneven. The purpose of this proposal is to generate data to address stigma in the public health system and intervene to overcome the challenges of youth with the navigation of health systems. The Brilhar e Transcender (BeT) study will include young trans women, aged 18 to 24, in Rio de Janeiro, Brazil. The BeT intervention has been found to be preliminarily efficacious in a pilot study. This proposal is for a study to test the effectiveness of an intervention to improve HIV prevention and care engagement among young trans women (N=150) at risk of HIV in Brazil.
Detailed description
Transvestites and young transsexual women in Brazil are exposed to a high risk of exposure to HIV and poor treatment of HIV infection. Brazil remains classified as a middle-income country in 2017 [1], despite the difficult political and economic climate. In 2016, there were 830,000 adults and children living with the HIV virus [2], with a 2% increase in new infections [2]. The first population-based study to assess HIV prevalence and knowledge of pre-exposure prophylaxis (PrEP) with young trans womenin Rio de Janeiro, Brazil (Transcender Study) found that 31.2% of them were infected with HIV. In this study, among young women aged 18 to 24 years, 24.2% of them were infected with HIV, a higher rate than any other study in young trans womenin the world [3, 4], and young women had three times as many unrecognized infections as adults [5]. These findings are worse than previous research suggests, that one in five transvestites or young transsexual women under the age of 25 was infected with the HIV virus [6, 7]. Even more worrisome, the young trans women in our study had had almost twice as much unprotected anal. Adverse events assessment and reporting sex in the past three months, while their perception of HIV risk was less than half. The data reflect that there is no decline in incident infections among young women and point to a need for early intervention to reduce the risk among transvestites and young transsexual women. This is a study in collaboration with the San Francisco Department of Public Health (SFDPH). All stages will be carried out in Brazil, at the National Institute of Infectious Diseases Evandro Chagas (INI)-FIOCRUZ. People (health professionals and trans people) will be referred from four services in Rio de Janeiro, Brazil, namely: INI-FIOCRUZ, Zilda Arns Family Clinic, Luiz Capriglione Diabetes and Endocrinology Institute (IEDE) and Heitor Municipal Health Center Beltron.
The study includes the collection of formative data, the evaluation of an anti-stigma campaign and an intervention study (pilot + scale-up) of HIV prevention and treatment. The expansion provides for a Type 1 hybrid design to assess the results of the exploratory implementation and examine the results of the single-arm intervention including 150 young transvestites and trans women. We will use a pre-post design to assess intervention outcomes and include an external comparison group using data extracted from the Ministry of Health to determine the effect of our intervention on engagement and adherence to PrEP and attachment to HIV care. Implementation results will also be explored with stakeholders at partner clinics, participants and key staff. In summary, formative data will be collected with 10 young young trans women to adapt a digital systems navigation and HIV prevention and care intervention to the cultural context and HIV prevention and care needs of this population group in Brazil. A highly visible and community-informed social marketing campaign will be developed and implemented to reduce anti-trans stigma at four SUS clinics in Rio de Janeiro. To measure success, pre- and post-campaign implementation interviews will be conducted with healthcare providers at the four clinics. Additionally, a pilot, phase I study will be conducted with 20 young participants to determine the preliminary effectiveness of the antistigma campaign and navigation systems intervention and demonstrate our ability to recruit young people in this population. Exit interviews will be conducted with all pilot participants (N = 20) to collect data to refine the intervention. Finally, an expansion of the pilot intervention study will be carried out, with the inclusion of another 150 participants. At this stage, all participants will receive the BeT intervention for a period of three months, in addition to standard care for HIV prevention and care. The study includes a Type 1 hybrid design study will be conducted to assess the results of the exploratory implementation and examine the results of the single-arm intervention including 150 transvestites and young trans women. We will use a pre-post design to assess intervention outcomes and include an external comparison group using data extracted from the Ministry of Health to determine the effect of our intervention on engagement and adherence to PrEP and attachment to HIV care. n total, the participants submitted to the intervention will stay in the project for one year. The initial visit will take approximately 2 hours to develop a case management plan with a team member (ARTAS plan). As part of the intervention, volunteers will be asked to participate in a baseline behavioral survey, followed by four others over one year (ie at 3, 6, 9, and 12 months). These surveys will last approximately 1 hour. During the intervention period, the volunteers will have contact with the digital browsers at least five times via WhatsApp or other social media to check the progress of the ARTAS plan and possibly more times depending on the participant's needs.
Each interaction should not last longer than an hour. In total, participants must spend 17 hours participating in the intervention, with no maximum time to adapt to the participant's needs. Recruitment for the study will feature the FIOCRUZ team of educators, composed of three members of the trans community, in addition to the possibility of peer recruitment. Both the confirmation of eligibility and the randomization process will be carried out with double verification. The inclusion visit will be carried out in person. After the consent and eligibility verification process, participants will be included in the study and will answer questionnaires administered by trained interviewers. The Shine and Transcender (BeT) intervention was based on ARTAS, an evidencebased, individual-level, multiple-session, time-limited intervention for system navigation and linkage for HIV treatment [29]. It lasts for 3 months and is composed of BeT sessions, digital interactions, asynchronous and automatic messages. Interim analysis of primary outcomes will be performed as described in Section 9.4.6, Planned Interim Analyzes. Analyzes considering HIV serological status (HIV-positive or -negative) will be performed in accordance with Section 9.4.7, Subgroup Analysis. With this study, it is expected to evaluate the modification associated with the BeT intervention in prevention (engagement and adherence to PrEP) and in HIV treatment (attachment to care). Clinical trials are a powerful tool for the evaluation of health interventions, whether drug or not. Through this study, it will be possible to assess the effectiveness of a digital intervention based on peer browsing in HIV prevention and care. As this is a study with only one arm, this can interfere with obtaining measurements or verifying outcomes. To minimize the possibility of bias, the assessment of outcomes will be performed by people other than those administering the intervention. In addition, we will benchmark against an outside group, with information from the Ministry of Health's national registry systems, to determine the effect of our intervention on engagement and adherence to PrEP and linkage to HIV care.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- With this study, it is expected to evaluate the modification associated with the BeT intervention in prevention (engagement and adherence to PrEP) and in HIV treatment (attachment to care). Clinical trials are a powerful tool for the evaluation of health interventions, whether drug or not. Through this study, it will be possible to assess the effectiveness of a digital intervention based on peer browsing in HIV prevention and care. As this is a study with only one arm, this can interfere with obtaining measurements or verifying outcomes. To minimize the possibility of bias, the assessment of outcomes will be performed by people other than those administering the intervention. In addition, we will benchmark against an outside group, with information from the Ministry of Health's national registry systems, to determine the effect of our intervention on engagement and adherence to PrEP and linkage to HIV care.
| Arm | Type | Receives |
|---|---|---|
| Arm 1 - Transvestites and young transsexual women | Experimental | Behavioral: InterviewQualitative interviews |
Who may qualify
- Ages
- 18 to 24 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterviewAlso: QueriesPilot study with digital browsers | Behavioural | Arm 1 - Transvestites and young transsexual women |
Primary outcome
Engagment on HIV prevention or care (for trans women)
Time frame: 10 months
Data from these surveys will be used to verify the primary outcomes of HIV testing, PrEP adoption, and attachment to HIV care. The results of this proposal could determine the preliminary effectiveness of the intervention in ensuring that trans youth undergo frequent HIV testing, engage in PrEP use and in HIV care.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2022.
- Derived from this study: PubMed 36735296Jalil EM, Wilson E, Monteiro L, Varggas T, Moura I, Torres TS, Hoagland B, Cardoso SW, Ismerio Moreira R, Goncalves Veloso Dos Santos V, Grinsztejn B; BeT Team. A Peer-Led Digital Intervention to Reduce HIV Prevention and Care Disparities Among Young Brazilian Transgender Women (The BeT Study): Protocol for an Intervention Study. JMIR Res Protoc. 2023 Feb 3;12:e44157. doi: 10.2196/44157.
- Individual participant dataSharing planned: No
Related trials for AIDS and Infections
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingObservational study
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
HIV
Active, not recruitingPhase 3
Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
HIV-1-infection, Non-Adherence, Medication
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
RecruitingObservational study
Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors
HIV
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Instituto Nacional de Infectologia Evandro Chagas (Fiocruz)
Rio de Janeiro, Brazil
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Interview in people with AIDS and Infections and HIV Prevention, run by Evandro Chagas National Institute of Infectious Disease at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Engagment on HIV prevention or care (for trans women) (time frame: 10 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05299645, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2022.